Guggenheim Initiates Coverage On InMed Pharmaceuticals with Buy Rating, Announces Price Target of $42

Benzinga · 1d ago
Guggenheim analyst Seamus Fernandez initiates coverage on InMed Pharmaceuticals (NASDAQ:INM) with a Buy rating and announces Price Target of $42.